Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Palisade Bio, Inc.

35 indications, side-by-side phase, drug & LoA

$1.66

-0.07 (-4.31%)

D 35Pipeline Score Overvalued Biotech · Clinical
Market Cap
338.48 M
EPS
-1.07
P/E Ratio
-
Value Trade
6.47 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    -

  • R&D Expenses

    6.00 M

  • Operating CF

    -3.89 M

  • Total Assets

    133.31 M

  • Total Liabilities

    5.95 M

  • Equity

    127.36 M

  • D/E Ratio

    12,345

8.33 %
Week
-30.36 %
1 Month
17.47 %
3 Month
-16.67 %
6 Month
-99.93 %
5 Year
-100 %
All Time
Cash Data
Healthy

  • Cash Position

    132.63 M

  • Monthly Burn

    1.30 M

  • Runway

    101.6 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
1.09 M
52 Week Range
0.53 - 2.86
% held by Insiders
1.51 %
% held by Institutions
88.86 %
Enterprise Value
205.85 M
Total Shares
165.95 M
Short %
15.75 %
Float Shares
164.96 M
Company Description
HQ: 7750 EL CAMINO REAL, SUITE 520...
Employees:14
https://www.palisadebio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data readout example
PALI-2108 Fibrostenotic Crohn's disease (FSCD)
Pre-clinical
—
Small Molecules
Digestive System
PALI-2108 Fibrostenotic Crohn's disease (FSCD)
Pre-clinical
—
Small Molecules
Digestive System
PALI-2108 Fibrostenotic Crohn's disease (FSCD)
Pre-clinical
—
Small Molecules
Digestive System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D35
Pipeline Score
$226M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.7x
rNPV / MCap
Top 42%
Micro Cap
(rank 526 of 905)
Percentile Rank
Palisade Bio, Inc. faces pipeline headwinds (35/100), with $565M risk-adjusted pipeline value, led by PALI-2108 in Fibrostenotic Crohn's Disease (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
PALI-2108
Small molecule		Fibrostenotic Crohn's DiseasePhase 1NCT0742809620% $378M ACTIVE NOT_RECRUITING 6 SLOW D (26) Mar 15, 2026MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
PALI-2108
ulcerative colitis,fibrostenotic Crohn’s disease
Phase 1b
2025-08-08
PALI-2108
ulcerative colitis,fibrostenotic Crohn’s disease
Phase 1b
2025-08-08
PALI-2108
ulcerative colitis,fibrostenotic Crohn’s disease
Phase 1b
2025-08-08
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PALI
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PALI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PALI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PALI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
PALI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
PALI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Palisade Bio, Inc. (PALI) News & Alerts
-
Tuesday, June 9, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How PALI ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Crohn's Disease #12 of 15 PHASE 1 PALI-2108
SNY LLY ABBV
$12.67B 0.89 FOLLOWER